Biodexa Prescribed drugs PLC BDRX inventory is buying and selling decrease on Thursday.
The corporate launched affected person updates on progression-free survival (PFS) and total survival (OS) from the continued MAGIC-1 research of MTX110 in recurrent glioblastoma (rGBM), a type of grownup mind most cancers.
The research evaluates the feasibility, security, and efficacy of treating rGBM sufferers with MTX110.
Additionally Learn: Most cancers-Targeted Nano-Cap Biodexa Prescribed drugs Inventory Is Surging On Thursday – Right here’s Why.
The corporate earlier reported that sufferers #1 and #2 in Cohort A achieved total survival (OS) of 12 and 13 months, respectively.
The remaining two sufferers in Cohort A stay on follow-up.
Affected person #3 has achieved 13 months of OS up to now, with six months of progression-free survival (PFS).
Affected person #4 has not progressed and has achieved 12 months of PFS and 12 months of OS up to now.
“The interim information from the MAGIC-G1 research has raised hopes that MTX110 may present a brand new remedy choice that provides actual advantages in survival with out the toxicity related to conventional chemotherapy,” the corporate says.
MTX110 has been evaluated for Diffuse midline glioma (DMG), a uncommon however extremely aggressive type of mind most cancers that always impacts youngsters, in two Section 1 trials.
A part 1 research carried out by the College of California, San Francisco (UCSF) concerned sufferers with DMG and reported a median total survival of 26.1 months. This contrasts with the historic median survival of round 10 months for sufferers with DMG.
In a separate part 1 trial involving newly identified DMG sufferers at Columbia College, MTX110 demonstrated, after solely two infusions per affected person, equally encouraging outcomes, enhancing median total survival to 16 months.
Value Motion: BDRX inventory is down 30.01% at $5.88 on the final verify Thursday.
Learn Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
